Announcement Highlights:
- Operating expenses decline significantly as Invion cycles through one-off payments in the previous quarter relating to its upcoming Ph I/II clinical trial.
- Invion announced positive in vivo results from study undertaken by Peter Mac on INV043 when used in combination with blockbuster ICIs.
- The company signs collaboration agreement with South Korea company Dr.inB, who will fund development Photosoft technology including PoC human trials on HPV.
- Ph I/II skin cancer trial is expected to start patient recruitment in coming months despite slower than expected processing of Invion's ethics application.
Invion Limited (ASX: IVX) wishes to provide the following update and Appendix 4C for the quarter ended 31 March 2024(3QFY24).
Invion Limited's Executive Chair and Chief Executive Officer Thian Chew commented:
"Invion has made a strong start to 2024 and the ground work we have invested in over the past few years has allowed us to secure a collaboration agreement with Dr.inB and given us additional validation in the potential of the Photosoft technology as we enter our clinical trial phase of development across multiple indications..."
View the full announcement here.
To learn more about Invion Limited and the company updates as a whole, subscribe to the Company's Chairman’s List.
